Abstracts tagged "autoimmune diseases"

Abstract Number: 0300 • ACR Convergence 2024
Evaluation of Long-term Primary Patency of Iliocaval Stenting in Patients with Retroperitoneal Fibrosis/chronic Periaortitis
Raymond Lay¹, Sara Achenbach², Cynthia Crowson¹, Umar Ghaffar¹, Michelle Burke¹, Haraldur Bjarnason¹, Newton Neidert¹, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Idiopathic retroperitoneal fibrosis (RPF) / chronic periaortitis (CP) is an uncommon condition characterized by a fibroinflammatory periarterial soft tissue thickening around the infra-renal abdominal…
Abstract Number: 0429 • ACR Convergence 2024
Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Rashmi Dhital¹, Kerri Bertrand², Essi Heinonen³ and Christina Chambers⁴, ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, CA, ³UC San Diego, La Jolla, CA; Karolinska Institutet, Stockholm, Sweden, San Diego, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic inflammation in autoimmune rheumatic diseases (ARDs) may alter human milk composition, akin to changes observed in other inflammatory states, indirectly impacting infant health,…
Abstract Number: 0658 • ACR Convergence 2024
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
Richard Furie¹, Amit Saxena², Samir Parikh³, Richard Leff⁴, Lucas Bohnett⁵, Kathryn Ray⁶, Brian Tuch⁴, Janet Anderl⁴, Jennifer Whang⁴ and Kiruthi Palaniswamy⁷, ¹Northwell Health, Manhasset, NY, ²NYU School of Medicine, New York, NY, ³Ohio State University, Columbus, OH, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, El Cajon, ⁶Kezar Life Sciences, Mill Valley, CA, ⁷Kezar Life Sciences, Inc, South San Francisco, CA
Background/Purpose: Zetomipzomib is a selective inhibitor of the immunoproteasome with anti-inflammatory and immunomodulatory potential without evidence of immunosuppression to date. The MISSION study (NCT03393013), a…
Abstract Number: 0783 • ACR Convergence 2024
Spatial Reconstruction of Interstitial Lung Disease
Miles Tran¹, Ce Gao¹, Mukta G Palshikar¹, Jessica Liu¹, Mari Kamiya¹, Gregory McDermott², Elena Joerns³, Daimon Simmons¹, Rachel Gate⁴, Deepak Rao⁵, Jeffrey Sparks⁶, Edy Kim⁷, Kevin Wei⁸ and ilya Korsunsky¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Mayo Clinic, Rochester, MN, ⁴10x Genomics, Pleasanton, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷Brigham and Women's Hospital, Cambridge, MA, ⁸Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Interstitial lung disease encompasses a heterogenous group of conditions broadly characterized by inflammation and progressive fibrosis of the lung[1]. There remains an ongoing search…
Abstract Number: 0898 • ACR Convergence 2024
A Blood Transcriptome Signature Distinguishes Between Diverse Systemic Autoimmune Diseases and Infection
Kleio-Maria Verrou¹, Argyrios Theophilopoulos², Nikolaos Vlachogiannis³, George Kollias⁴, Christoforos Nikolaou⁵ and Petros Sfikakis¹, ¹Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Department of Immunology, Scripps Clinic and Research Foundation, San Diego, CA, ³Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Zografou, Greece, ⁴Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Institute for Bioinnovation, Biomedical Sciences Research Center “Alexander Fleming”, Vari, Greece. Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Institute for Bioinnovation, Biomedical Sciences Research Center “Alexander Fleming”, Athens, Greece
Background/Purpose: The most pathogenic responses against self and foreign antigens that lead to systemic autoimmune diseases and infections, respectively, overall engage similar immunologic components. Consequently, there are…
Abstract Number: 0970 • ACR Convergence 2024
Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity
Rebecca Ross¹, Poli Adi Narayanna Reddy², Joseph Salvino², Elton Zeqiraj³ and Francesco Del Galdo³, ¹Medicine and Health, University of Leeds, Leeds, United Kingdom, ²The Wistar Institute, Philadelphia, PA, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Increased Type I IFN activation plays a key role in Scleroderma (SSc), Systemic Lupus Erythematosus and Inflammatory Myositis. Deubiquitylase (DUB) BRCC36 isopeptidase complex (BRISC)…
Abstract Number: 1130 • ACR Convergence 2024
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
Melanie Hagen¹, Laura Bucci¹, Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
Abstract Number: 1415 • ACR Convergence 2024
Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study
Astrid Rasmussen¹, Alan Baer², Thomas Grader-Beck³, Margaret Beach⁴, Blake M. Warner⁵, Christopher Lessard¹, A. Darise Farris¹ and Robert Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins, Baltimore, MD, ⁴NIH/NIDCR, Arlington, VA, ⁵National Institutes of Health, Bethesda, MD
Background/Purpose: Metformin (Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In in vitro studies and human trials in SLE…
Abstract Number: 1575 • ACR Convergence 2024
Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis
Kevin Chevalier¹, Guillaume Chassagnon², Sarah LOUIS-LEONARD³, Pascal cohen⁴, bertrand Dunogue⁵, Alexis Régent⁶, Benjamin Thoreau⁵, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of Radiology, Hôpital Cochin, AP-HP. Centre Université Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France, Paris, France, ³Sorbonne Université, INSERM, Department of Neurormyologie and Neuropathology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic disease within the connective tissue disease (CTD) spectrum. It is characterized by microcirculatory abnormalities, skin and internal…
Abstract Number: 1693 • ACR Convergence 2024
Change in Forced Vital Capacity at Week 12 or 24 Has Prognostic Value for Outcome at Week 52 in Patients with Autoimmune Disease-Related Interstitial Lung Diseases
Anna-Maria Hoffmann-Vold¹, Margarida Alves², Corinna Miede³ and Oliver Distler⁴, ¹Oslo University Hospital, Oslo, Norway, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Clinical trials in patients with interstitial lung diseases (ILDs) generally include a 52-week treatment period. Shorter trials would help speed up drug development and…
Abstract Number: 1828 • ACR Convergence 2024
SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling
Christopher Wasson¹, Stefano Di Donato², Rebecca Ross³, Vishal Kakkar⁴ and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁴LIRMM University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis is an autoimmune disease which is characterized by fibrosis of the skin and the internal organs with variable severity. Type I interferon…
Abstract Number: 1895 • ACR Convergence 2024
Association Between a History of Mental Illness and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-based Case-control Study
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Clinical studies have shown high prevalence rates of mental illnesses in patients with autoimmune diseases. A recent animal study revealed that social stress induces…
Abstract Number: 2036 • ACR Convergence 2024
CCN6 Gene Mutation Induces Mitochondrial Dysfunction: The Cause of Progressive Pseudo-rheumatoid Dysplasia
Yanhong Li¹, Xiufeng Bai² and Yi Liu³, ¹West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, ²West China Hospital, Sichuan University, Chengdu, Sichuan, China (People's Republic), ³West China Hospital of Sichuan University, Chengdu, Sichuan, China
Background/Purpose: Progressive pseudo-rheumatoid dysplasia (PPRD) is a rare autosomal recessive disorder characterized by non-inflammatory joint issues that primarily affect the articular cartilage. This leads to…
Abstract Number: 2263 • ACR Convergence 2024
The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Gilad Halpert¹, Ori Moskovitch², Linoy Israel², Eri Govrin², Boris Gilburd², Ori Segal², Adi Anaki³, Tal Caller², Daniel Yechiali², Shlomo Segev², Omer Gendelman⁴, Abdulla Watad⁵, Ruty Mehrian-Shai², Rachella Popovtzer³ and Howard Amital⁶, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Ramat-Gan, Israel, ³Bar Ilan University, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].